Anakinra

Generic Name
Anakinra
Brand Names
Kineret
Drug Type
Biotech
Chemical Formula
-
CAS Number
143090-92-0
Unique Ingredient Identifier
9013DUQ28K
Background

Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...

Indication

Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...

Associated Conditions
Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
Associated Therapies
-
Clinical Trials
Related News

Studying Anakinra to Reduce Secondary Brain Damage After Spontaneous Haemorrhagic Stroke

Phase 2
Recruiting
Conditions
Intracerebral Hemorrhage
Interventions
Drug: Anakinra
First Posted Date
2021-04-08
Last Posted Date
2024-11-18
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
75
Registration Number
NCT04834388
Locations
🇳🇱

Radboudumc, Nijmegen, Netherlands

suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19

Phase 3
Completed
Conditions
Covid19
Interventions
Drug: Placebo
Drug: Anakinra
First Posted Date
2020-12-23
Last Posted Date
2022-09-06
Lead Sponsor
Hellenic Institute for the Study of Sepsis
Target Recruit Count
606
Registration Number
NCT04680949
Locations
🇬🇷

1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO, Athens, Greece

🇬🇷

1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece

🇬🇷

3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S., Athens, Greece

and more 37 locations

A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment

First Posted Date
2020-12-07
Last Posted Date
2024-02-28
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
84
Registration Number
NCT04656184
Locations
🇫🇷

CHU de Bicêtre, Le Kremlin-Bicêtre, Val De Marne, France

Anakinra in the Management of COVID-19 Infection

First Posted Date
2020-11-25
Last Posted Date
2022-08-16
Lead Sponsor
Hamad Medical Corporation
Target Recruit Count
80
Registration Number
NCT04643678
Locations
🇶🇦

Hamad Medical Corporation, Doha, Qatar

Anakinra, COVID-19, Cytokine Storm

First Posted Date
2020-10-27
Last Posted Date
2022-01-25
Lead Sponsor
Weill Medical College of Cornell University
Registration Number
NCT04603742
Locations
🇺🇸

Weill Cornell Medcine, New York, New York, United States

A Study of JNJ-77474462 in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: JNJ-77474462
Drug: Anakinra
First Posted Date
2020-09-10
Last Posted Date
2023-06-29
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
78
Registration Number
NCT04544813
Locations
🇦🇺

Nucleus Network, Q-Pharm Pty Ltd, Herston, Australia

Randomised Evaluation of COVID-19 Therapy

First Posted Date
2020-05-11
Last Posted Date
2024-01-05
Lead Sponsor
University of Oxford
Target Recruit Count
70000
Registration Number
NCT04381936
Locations
🇻🇳

Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam

🇬🇭

Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana

🇮🇳

Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India

and more 4 locations

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

First Posted Date
2020-04-24
Last Posted Date
2024-11-21
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
27
Registration Number
NCT04359784
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Early Treatment of Cytokine Storm Syndrome in Covid-19

Phase 3
Completed
Conditions
Cytokine Storm
COVID-19
Interventions
Drug: Normal saline
Drug: Anakinra
First Posted Date
2020-04-24
Last Posted Date
2023-08-24
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
32
Registration Number
NCT04362111
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)

First Posted Date
2020-04-22
Last Posted Date
2023-07-13
Lead Sponsor
Hellenic Institute for the Study of Sepsis
Target Recruit Count
1000
Registration Number
NCT04357366
Locations
🇬🇷

Department of Internal Medicine, University General Hospital of Larissa, Larissa, Greece

🇬🇷

2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO, Piraeus, Greece

🇬🇷

COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece

and more 25 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy